Utilization of cytokeratin-based biomarkers for pharmacodynamic studies

Expert Review of Molecular Diagnostics

Volumn 10, Issue 3, 2010, Pages 353-359

  Linder, Stig ^a   Olofsson, Maria Hägg ^a   Herrmann, Richard ^a,b   Ulukaya, Engin ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Peviva AB   (Sweden)

^c ULUDAG UNIVERSITY   (Turkey)

Author keywords

Apoptosis; M30 Apoptosense ELISA; M65 ELISA; Necrosis; Pharmacodynamic marker

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN; CYTOKERATIN 18; MONOCLONAL ANTIBODY;

APOPTOSIS; CANCER THERAPY; CARCINOMA; CELL DEATH; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MACROMOLECULE; PHARMACODYNAMICS; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; TUMOR CELL;

BIOLOGICAL MARKERS; CELL DEATH; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KERATIN-18; NEOPLASMS;

EID: 77950621989     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.14     Document Type: Review

References (53)

1. Sutherland DJ. Hormones and cancer. In: The Basic Science of Oncology. Tannock IF, Hill RP (Eds). Pergamon Press, NY, USA 204-222 (1987).
2. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
3. Belhocine T, Steinmetz N, Hustinx R et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res. 8(9), 2766-2774 (2002).
4. De Saint-Hubert M, Prinsen K, Mortelmans L et al. Molecular imaging of cell death. Methods 48 (2), 178-187 (2009).
5. Thomson DM, Krupey J, Freedman SO et al. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc. Natl Acad. Sci. USA 64(1), 161-167 (1969).
6. Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol. Clin. North Am. 30 (4), 677-686 (2003).
7. Gion M, Mione R, Barioli P et al. Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Anticancer Res. 16(4B), 2279-2284 (1996).
8. Ghanem G, Loir B, Morandini R et al. On the release and half-life of S100B protein in the peripheral blood of melanoma patients. Int. J. Cancer 94(4), 586-590 (2001).
9. Beck EP, Moldenhauer A, Merkle E et al. CA 125 production and release by ovarian cancer cells in vitro. Int. J. Biol. Markers 13(4), 200-206 (1998).
10. Stigbrand T. The versatility of cytokeratins as tumor markers. Tumour Biol. 22(1), 1-3 (2001).
11. Linder S. Cytokeratin markers come of age. Tumour Biol. 28(4), 189-195 (2007).
12. Cocco RE, Ucker DS. Distinct modes of macrophage recognition for apoptotic and necrotic cells are not specified exclusively by phosphatidylserine exposure. Mol. Biol. Cell 12(4), 919-930 (2001).
13. Brouckaert G, Kalai M, Krysko DV et al. Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol. Biol. Cell 15(3), 1089-1100 (2004).
14. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu. Rev. Physiol. 60, 619-642 (1998). (Pubitemid 28157889)
15. Chang YS, di Tomaso E, McDonald DM et al. Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. Proc. Natl Acad. Sci. USA 97(26), 14608-14613 (2000).
16. Liotta L, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res. 34, 997-1004 (1974).
17. Swartz MA, Kristensen CA, Melder RJ et al. Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity. Br. J. Cancer 81(5), 756-759 (1999).
18. Larson CJ, Moreno JG, Piento KJ et al. Apoptosis of circulating tumor cells in prostate cancer patients. Cytometry A 62(1), 46-53 (2004).
19. Linder S, Havelka AM, Ueno T et al. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett. 214(1), 1-9 (2004).
20. Hou JM, Greystok A, Lancashire L et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am. J. Pathol. 175(2), 808-816 (2009).
21. Moll R. Molecular diversity of cytokeratins: significance for cell and tumor differentiation. Acta Histochemica. Suppl. 41, 117-127 (1991).
22. Björklund B. Tissue polypeptide antigen (TPA): Biology, biochemistry, improved assay methodology, clinical significance in cancer and other conditions, and future outlook. Antibiot. Chemother. 22, 16-31 (1978).
23. Weber K, Osborne M, Moll R et al. Tissue polypeptide antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia: re- evaluation of a human tumor marker. EMBO J. 3(11), 2707-2714 (1984).
24. Rydlander L, Ziegler E, Bergman T et al. Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur. J. Biochem. 241(2), 309-314 (1996).
25. Stieber P, Hasholzner U, Bodenmuller H et al. CYFRA 21-1. A new marker in lung cancer. Cancer 72(3), 707-713 (1993). (Pubitemid 23215254)
26. Chou CF, Riopel CL, Rott LS et al. A significant soluble keratin fraction in 'simple' epithelial cells. Lack of an apparent phosphorylation and glycosylation role in keratin solubility. J. Cell Sci. 105(Pt 2), 433-444 (1993).
27. Nishibori H, Matsuno Y, Iwaya M et al. Human colorectal carcinomas specifically accumulate Mr 42,000 ubiquitin-conjugated cytokeratin 8 fragments. Cancer Res. 56(12), 2752-2757 (1996).
28. Bergman AC, Benjamin T, Alaiya A et al. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 21(3), 679-686 (2000).
29. Olofsson MH, Cummings J, Fayad W et al. Specific demonstration of drug-induced tumour cell apoptosis in human xenografts models using a plasma biomarker. Cancer Biomark. 5(3), 117-125 (2009).
30. Sundström BE, Stigbrand TI. Cytokeratins and tissue polypeptide antigen. Int. J. Biol. Markers 9(2), 102-108 (1994).
31. Cummings J, Ranson M, Butt F et al. Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother. Pharmacol. 60(6), 921-924 (2007).
32. Caulin C, Salvesen GS, Oshima RG. Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J. Cell Biol. 138(6), 1379-1394 (1997).
33. Ku NO, Liao J, Omary MB. Apoptosis generates stable fragments of human type I keratins. J. Biol. Chem. 272(52), 33197-33203 (1997).
34. Leers MP, Kölgen W, Björklund V et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J. Pathol. 187(5), 567-572 (1999).
35. Kramer G, Erdal H, Mertens HJ et al. Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res. 64(5), 1751-1756 (2004).
36. Hägg M, Biven K, Ueno T et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest. New Drugs 20(3), 253-259 (2002).
37. Ueno T, Toi M, Bivén K et al. Measurement of an apoptosis product in the sera of breast cancer patients. Eur. J. Cancer 39, 769-774 (2003).
38. Demiray M, Ulukaya EE, Arslan M et al. Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. Cancer Invest. 24(7), 669-676 (2006).
39. Koelink PJ, Lamers CB, Hommes DW et al. Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 9, 88 (2009).
40. Ausch C, Buxhofer-Ausch V, Olszewski U et al. Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur. J. Surg. Oncol. 35(11), 1164-1168 (2009).
41. Ulukaya E, Yilmaztepe A, Akgoz S et al. The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56(3), 399-404 (2007).
42. Kramer G, Schwarz S, Hagg M et al. Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br. J. Cancer 94(11), 1592-1598 (2006).
43. de Haas EC, di Pietro A, Simpson KL et al. Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer. Neoplasia 10(10), 1041-1048 (2008).
44. Ozturk B, Coskun U, Sancak B et al. Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int. Immunopharmacol. 9(5), 645-648 (2009).
45. Dive C, Smith RA, Garner E et al. Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br. J. Cancer 102(3), 577-582 (2010).
46. Scott LC, Evans TR, Cassidy J et al. Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response. Br. J. Cancer 101(3), 410-417 (2009).
47. Olofsson MH, Ueno T, Pan Y et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin. Cancer Res. 13(11), 3198-3206 (2007).
48. Cummings J, Hodgkinson C, Odedra R et al. Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activity. Mol. Cancer Ther. 7(3), 455-463 (2008). (Pubitemid 351482128)
49. Micha D, Cummings J, Shoemaker A et al. Circulating biomarkers of cell death after treatment with the BH-3 mimetic ABT-737 in a preclinical model of small-cell lung cancer. Clin. Cancer Res. 14(22), 7304-7310 (2008).
50. Koopman G, Reutelingsperger CP, Kuijten GA et al. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84(5), 1415-1420 (1994). (Pubitemid 24273007)
51. Kaufmann SH, Vaux DL. Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene 22(47), 7414-7430 (2003). (Pubitemid 37487167)
52. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev. 20(1), 1-15 (2006).
53. Berndtsson M, Hagg M, Panaretakis T et al. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int. J. Cancer 120(1), 175-180 (2007). (Pubitemid 44901933)